Pacific Parkinson's Research Centre
Vancouver, British Columbia, V6T 2B5, Canada
Location status: Recruiting
Location contact
A. Jon Stoessl, MD
SUB_INVESTIGATOR
Jess McKenzie
CONTACT
Vesna Sossi, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT04426786
There is increasing evidence that the usage and delivery of energy to the brain, known as brain energetics, is altered in people with Parkinson's disease (PD). This project will explore whether exercise has a positive impact on brain energetics using functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) brain scanning in PD subjects.
PD subjects will be scanned before and after a supervised exercise program to investigate the effect of exercise on brain energetics. In a separate study, the investigators will also scan healthy volunteers to compare brain energetics in the healthy brain with the brain energetics data in PD subjects acquired in this study.
Interested in participating?
Request Info40 year–80 year
All sexes
Interventional
Not applicable
Vancouver, British Columbia, V6T 2B5, Canada
Location status: Recruiting
A. Jon Stoessl, MD
SUB_INVESTIGATOR
Jess McKenzie
CONTACT
Vesna Sossi, PhD
PRINCIPAL_INVESTIGATOR
Previous work has investigated the link between decreased brain energetics (through mitochondrial dysfunction), though an investigation in-vivo has never been feasible due to technology constraints. Furthermore, recent work has suggested exercise may help reduce the effect of mitochondrial dysfunction. There is thus compelling evidence to investigate brain energetics/mitochondrial function in-vivo, in health, at different stages of disease and the relationship to exercise. While such measurements are intrinsically difficult, a useful measure is expected to be derived from the ratio between the cerebral metabolic rate of oxygen (CMRO2) and the cerebral metabolic rate of glucose (CMRGlu), if they are measured simultaneously. The simultaneous aspect of the two measurements is extremely important as diurnal variations in CMRO2 can be as high as 20%, while those in CMRGlu as high as 38%. Fortunately, given recent advances in measurement technique and instrumentation development, such studies are now becoming possible: CMRO2 can be obtained using very advanced functional magnetic resonance imaging (fMRI) techniques with respiratory manipulations, while CMRGlu can be estimated by positron emission tomography (PET) using the tracer 18F-fluorodeoxyglucose (FDG-PET). A lower-than-normal ratio between CMRO2 and CMRGlu coupled with a decrease in CMRGlu in any brain area is taken to be indicative of locally impaired brain energetics, related to altered mitochondrial function.
The investigators hypothesize that (i) brain energetics, measured as the ratio CMRO2/CMRGlu is altered early in Parkinson's disease (PD) compared to age-matched healthy controls (HC) and continues to be altered as disease progresses; and (ii) exercise will positively affect alterations in brain energetics in PD subjects.
The investigators will recruit up to 30 PD subjects who are not habitual exercisers and up to 10 PD subjects who are habitual exercises. The 30 non-exercisers will undergo a supervised six month exercise intervention in groups, with PET/MRI scans before and after. The 10 exercisers will only be scanned once (for observational comparisons with the non-exercisers at baseline) and will not undergo the exercise intervention. In a separate study, the investigators will recruit up to 30 HCs to compare to compare their brain energetics metrics with those of the PD subjects at baseline to test hypothesis (i). Of the 30 non-exercisers, half will be assigned to start the exercise intervention immediately after their baseline scan, and the other half will have a six month delayed start to the intervention. During the delay, subjects will perform passive exercise in groups, to control for social interaction and possible placebo effects. Longitudinal comparisons of the non-exercisers before and after the intervention will test hypothesis (ii).
The objectives of this study are twofold: to (i) investigate a disease-initiating mechanism (abnormal mitochondrial function and impaired cellular bioenergetics), which could constitute a novel therapeutic target; and to (ii) study the effects of the intervention: while this will be a pilot study, involving limited exercise regimens, any knowledge gained about the impact of exercise on brain energetics will have a tremendous impact on the design of neuroprotective therapies and personalized treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
General exclusion criteria:
MRI-specific exclusion criteria:
Subjects may be excluded following study enrollment if they meet any of the following exclusion criteria:
Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.
Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.
Time frame: Six months
CMRO2 will be computed from MRI data and CMRGlu from PET data; their ratio will be used to assess brain energetics.
Time frame: Six months
Motor function will be assessed using the MDS-Unified Parkinson's Disease Rating Scale (part III). The scale consists of 18 questions with each assigned a value in the range 0-4. Higher values indicate increasingly severe motor complications.
Time frame: Six months
Cognitive function will be assessed using the Montreal Cognitive Assessment. The assessment produces a score out of 30. Lower scores indicate increasingly impaired cognitive function.
Contact information is provided by the study sponsor or research team.
Pacific Parkinson's Research Centre
Other
The Effect of Exercise on Brain Energetics in Parkinson's Disease
Acronym: EBEPD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04804202
Basal Ganglia Diseases, Behavior
Newark, New Jersey, United States
View Trial DetailsNCT07382674
Basal Ganglia Diseases, Behavior
Atlanta, Georgia, United States
View Trial DetailsNCT05644327
Basal Ganglia Diseases, Behavior
Laval, Quebec, Canada
View Trial DetailsNCT06088355
Basal Ganglia Diseases, Behavior
Decatur, Georgia, United States
View Trial Details